"Eastern Connecticut Hematology and Oncology (ECHO) Associates is proud to provide expert hematology and oncology care to patients across Eastern Connecticut for over 30 years. Our goal to provide patients and their families with access to the latest treatments and resources in a personalized and compassionate manner. We are a private practice, with the benefits of affiliations with top hospitals in the area. We are independently owned, meaning your needs come first. We go the extra mile to deliver outstanding, cost-efficient care, and ongoing emotional support."

During the past decade, Eastern Connecticut Hematology and Oncology Associates conducted 61 clinical trials. In the 10-year time frame, 61 clinical trials started and 75 clinical trials were completed, i.e. on average, 123% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 38 clinical trials were completed. i.e. 172.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Eastern Connecticut Hematology and Oncology Associates" #1 sponsor was "National Cancer Institute (NCI)" with 32 trials, followed by "SWOG Cancer Research Network" with 16 trials sponsored, "Alliance for Clinical Trials in Oncology" with 7 trials sponsored, "Hoffmann-La Roche" with 7 trials sponsored and "NSABP Foundation Inc" with 7 trials sponsored. Other sponsors include 68 different institutions and companies that sponsored additional 46 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Eastern Connecticut Hematology and Oncology Associates" #1 collaborator was "National Cancer Institute (NCI)" with 42 trials as a collaborator, "Cancer and Leukemia Group B" with 10 trials as a collaborator, "NCIC Clinical Trials Group" with 9 trials as a collaborator, "NRG Oncology" with 9 trials as a collaborator and "SWOG Cancer Research Network" with 8 trials as a collaborator. Other collaborators include 59 different institutions and companies that were collaborators in the rest 47 trials.

According to Clinical.Site data, the most researched conditions in "Eastern Connecticut Hematology and Oncology Associates" are "Breast Cancer" (14 trials), "Prostate Cancer" (9 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials) and "Non-Small Cell Lung Cancer" (6 trials). Many other conditions were trialed in "Eastern Connecticut Hematology and Oncology Associates" in a lesser frequency.

Most popular intervention types in "Eastern Connecticut Hematology and Oncology Associates" are "Drug" (121 trials), "Other" (49 trials), "Biological" (39 trials), "Procedure" (13 trials) and "Radiation" (12 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (32 trials), "Carboplatin" (22 trials), "Paclitaxel" (19 trials), "Bevacizumab" (17 trials) and "Quality-of-Life Assessment" (17 trials). Other intervention names were less common.

The vast majority of trials in "Eastern Connecticut Hematology and Oncology Associates" are 104 trials for "All" genders, 25 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are NaN active trials in "Eastern Connecticut Hematology and Oncology Associates". undefined are not yet recruiting, 23 are recruiting, 45 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 56 completed trials in Eastern Connecticut Hematology and Oncology Associates, 1 suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Eastern Connecticut Hematology and Oncology Associates, 5 "Phase 1" clinical trials were conducted, 42 "Phase 2" clinical trials and 93 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".